Impact of PTEN Protein Expression on Benefit From Adjuvant Trastuzumab in Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the North Central Cancer Treatment Group N9831 Trial

PURPOSE: It has been suggested that PTEN, a negative regulator of PI3K/AKT signaling, is involved in tumor sensitivity to trastuzumab. We investigated the association between tumor PTEN protein expression and disease-free survival (DFS) of patients randomly assigned to receive chemotherapy alone (ar...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Główni autorzy: Perez, Edith A., Dueck, Amylou C., McCullough, Ann E., Chen, Beiyun, Geiger, Xochiquetzal J., Jenkins, Robert B., Lingle, Wilma L., Davidson, Nancy E., Martino, Silvana, Kaufman, Peter A., Kutteh, Leila A., Sledge, George W., Harris, Lyndsay N., Gralow, Julie R., Reinholz, Monica M.
Format: Artigo
Język:Inglês
Wydane: American Society of Clinical Oncology 2013
Hasła przedmiotowe:
Original Reports
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3731983/
https://ncbi.nlm.nih.gov/pubmed/23650412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.42.2642
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy